No. of tests
EliA Anti-IgA -
not for sale in the U.S.
||2 x 12
Purified human IgA
Flyer on EliA Anti-IgA (pdf)
Disease association and antibody prevalence
- 40% of patients with selective IgA deficiency
- 10 to 25% of patients with Common Variable Immunodeficiency (CVID)
Selective IgA deficiency is most common in celiac disease, while CVID is the most common symptomatic primary immunodeficiency (prevalence ~ 0.004 %) characterized by low serum levels of IgG, IgA and variably IgM.
Prevent anaphylactoid reactions
Immunoglobulin G (IgG) replacement therapy represents an effective prophylaxis for infections in CVID patients. However, in any given IgG product, traces of IgA (0.05 to 6.0 mg/dl depending on the product) can be found. Therefore, patients with anti-IgA antibodies are at risk to develop an anaphylactoid reaction to these IgG formulations, especially upon intravenous andministration. The frequency of transufsion reactions is approximately 1 in 30,000 in the general population, while it is as high as up to 1 in 30 in IgA deficiency.
When is the measurement recommended?
Patients who have IgA deficiency and are destined for blood transfusion or IgG replacement therapy.
Celiac disease patients who are IgA deficient in order to assess a future risk for blood transfusions.
Any IgA deficient patient in order to assess a future risk for blood transfusions.
Thon (2010) |
Yuan S and Goldfinger D (2008) |
Kumar V et al (2002) |
Horn J et al (2006) |
Lilic D and Sewell WAC (2008) |
Brown R et al (2008
Back to top